ACADIA Pharmaceuticals Competitors and Similar CompaniesClear all
ACADIA Pharmaceuticals's competitors and similar companies include Neuraly, Alector, Supernus Pharmaceuticals and Omeros.
 ACADIA Pharmaceuticals ACADIA Pharmaceuticals (formerly Receptor Technologies) is a biopharmaceutical company developing medicines that address medical needs in related central nervous system (CNS) disorders. |  Neuraly Neuraly is a clinical-stage biotechnology company that specializes in the development of drugs for neurodegenerative diseases. |  Alector Alector is a biotechnology company that develops therapies for the treatment of neurodegenerative diseases. |  Supernus Pharmaceuticals Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. |  Omeros Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers. | |
Founding Date | Founding Date 1993 | Founding Date 2016 | Founding Date 2013 | Founding Date 2005 | Founding Date 1994 |
Type | Type Public | Type Subsidiary | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations San Diego, US HQ Princeton, US | Locations Gaithersburg, US HQ | Locations San Francisco, US HQ | Locations Rockville, US HQ | Locations Seattle, US HQ |
Employees | Employees 513 | Employees 186% increase | Employees 2382% decrease | Employees 6527% increase | Employees 1968% decrease |
Valuation ($) | Valuation ($) 2.4 b | Valuation ($) N/A | Valuation ($) 495.3 m | Valuation ($) 1.9 b | Valuation ($) 248.6 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $1.1b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $21m (FY, 2025) | Revenue (est.) $719m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods $89m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods $74.6m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $982.5m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit $644.4m (FY, 2025) | Gross profit N/A |
Net income | Net income $391m (FY, 2025) | Net income N/A | Net income ($142.9m) (FY, 2025) | Net income ($38.6m) (FY, 2025) | Net income ($3.4m) (FY, 2025) |
Operating ⚠ | |||||
Patents (US) | Patents (US) 47 (FY, 2021) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 80 (FY, 2021) |
Phase I Trials Products | Phase I Trials Products 1 (FY, 2021) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 3 (FY, 2021) |
Phase II Trials Products | Phase II Trials Products 1 (FY, 2021) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 2 (FY, 2021) |
Phase III Trials Products | Phase III Trials Products 3 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 2 (FY, 2021) |
Products Marketed | Products Marketed 1 (FY, 2021) | Products Marketed N/A | Products Marketed N/A | Products Marketed N/A | Products Marketed 1 (FY, 2021) |
Funding | |||||
Total funding raised | Total funding raised $ 770.8m | Total funding raised $ 36m | Total funding raised $ 194.5m | Total funding raised $ 69.5m | Total funding raised $ 354.8m |
For sources of this data, please see the company profile
View Company Profiles
Neuraly
HQ
Gaithersburg, US
Neuraly is a clinical-stage biotechnology company that specializes in the development of drugs for neurodegenerative diseases.
View companyAlector
HQ
San Francisco, US
Employees
238↓ 2% decrease
Alector is a biotechnology company that develops therapies for the treatment of neurodegenerative diseases.
View companySupernus Pharmaceuticals
HQ
Rockville, US
Employees
652↑ 7% increase
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders.
View companyOmeros
HQ
Seattle, US
Employees
196↓ 8% decrease
Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers.
View company